U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06941129) titled 'CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases' on April 16.
Brief Summary: CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Study Start Date: Feb. 11
Study Type: INTERVENTIONAL
Condition:
SLE
Systemic Sclerosis (SSc)
Inflammatory Myopathy
ANCA-Associated Vasculitis (AAV)
Intervention:
BIOLOGICAL: UCAR T-cell
universal allogeneic anti-CD19/BCMA CAR T-cells
Recruitment Status: RECRUITING
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Disclaimer: Curated by HT Syndication....